Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Intensified CHOP Plus Rituximab (R-CHOP 14) Versus CHOP Plus Rituximab (R-CHOP 21) and Frontline/Prophylactic Darbepoetin Alfa Treatment Versus Usual Symptomatic Treatment of Anemia in Patients Aged 60 to 80 Years With Diffuse Large B-cell Lymphoma.

NCT00144755 is registered in ClinicalTrials.gov with Lymphoma Study Association as lead sponsor.

NCT NCT00144755
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00144755 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Intensified CHOP Plus Rituximab (R-CHOP 14) Versus CHOP Plus Rituximab (R-CHOP 21) and Frontline/Prophylactic Darbepoetin Alfa Treatment Versus Usual Symptomatic Treatment of Anemia in Patients Aged 60 to 80 Years With Diffuse Large B-cell Lymphoma.
Lead sponsor
Lymphoma Study Association
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2003
Completion date
December 31, 2012
Enrollment
600 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large cell lymphoma